Preoperative risk factors for extraurothelial recurrence in N0M0 patients with renal pelvic cancer treated by radical nephroureterectomy

The prediction of extraurothelial recurrence (EUR) before radical nephroureterectomy (RNU) is difficult for patients with upper tract urothelial carcinoma. If EUR can be predicted preoperatively, it may be possible to determine the need for neoadjuvant chemotherapy or the surgical strategy.

Our previous study identified preoperative risk factors for EUR in ureteral cancer, while the present study identified preoperative risk factors for EUR in renal pelvic cancer (RPC). The preoperative factors were reviewed in 71 N0M0 patients with RPC treated by RNU between 1999 and 2013. Preoperative clinical background data, laboratory test results, including inflammatory indices, lactate dehydrogenase (LDH), and estimated glomerular filtration rate, and radiological findings were subjected to multivariate analyses to identify independent predictive factors for EUR. The 3-year EUR-free survival (EURFS) rate was 81.9%, and univariate analysis showed that clinical T (cT) stage ≥3, white blood cell counts ≥7600/µl, neutrophil counts ≥4,500/µl, neutrophil-to-lymphocyte ratio ≥2.0, and LDH ≥210 IU/l were significantly associated with EURFS. Additionally, a cT stage ≥3 (P=0.0244) and LDH ≥210 IU/l (P=0.0322) were independent predictors for EUR. When patients were stratified into three groups according to the number of risk factors, the 3-year EURFS rates were 94.5, 76.3, and 33.3% for the low-, intermediate-, and high-risk patient groups, respectively. In conclusion, cT stage ≥3 and LDH ≥210 IU/l were preoperative predictive factors of EUR in patients with RPC. High-risk patients may be candidates for neoadjuvant chemotherapy and low-risk patients may be candidates for RNU without lymph node dissection.

Molecular and clinical oncology. 2016 Jan 28 [Epub]

Keiichi Ito, Junichi Asakuma, Kenji Kuroda, Kazuyoshi Tachi, Akinori Sato, Akio Horiguchi, Kenji Seguchi, Tomohiko Asano

Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan., Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan., Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan., Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan., Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan., Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan., Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan., Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe